Skip to main content
Top
Published in: Esophagus 1/2016

01-01-2016 | Original Article

Role of fibroblast growth factor receptors in esophageal squamous cell carcinoma

Authors: Yutaka Shimada, Tomoyuki Okumura, Yoshinori Takei, Kazuaki Watanabe, Takuya Nagata, Takashi Hori, Soken Tsuchiya, Kazuhiro Tsukada, Kazuharu Shimizu

Published in: Esophagus | Issue 1/2016

Login to get access

Abstract

Background

We previously reported that the expression of fibroblast growth factor receptor-like 1 (FGFRL1) was associated with the progression of esophageal squamous cell carcinoma (ESCC). However, the clinical roles of FGFR1, FGFR2, FGFR3, and FGFR4 in ESCC have not yet been examined in detail. Furthermore, it currently remains unclear why FGFRL1 is a prognostic factor for ESCC.

Materials and methods

A squamous cell carcinoma tissue microarray established in Toyama University was used to evaluate the expression of the 4 FGFRs. Sixty-nine ESCC specimens were obtained from patients who had undergone surgery between 1990 and 2008. The immunohistochemical results obtained herein were compared to those for FGFRL1 from our previous study. We also determined whether FGFRL1 bound to other FGFRs that were selected using the tissue microarray analysis.

Results

The frequency of different FGFR overexpression combinations revealed that FGFRL1, FGFR1, and FGFR4 were the predominant types. In contrast to FGFRL1, no association was observed between the expression of each FGFR and patient prognosis. Regarding the combination analysis, patients that co-expressed FGFRL1 and FGFR1 had the worst prognosis, while patients who tested negative for the expression of both FGFRL1 and FGFR4 had the best prognosis. The results of the proximity ligation assay demonstrated that FGFRL1 bound to FGFR1 and FGFR4.

Conclusions

Of the 5 FGFRs examined, the expression of FGFRL1 was the main prognostic factor in ESCC patients. FGFR1 and FGFR4 may be sub-driving factors of ESCC as well as the main targets of the heterodimer of FGFRL1.
Literature
1.
go back to reference Ozawa S, Tachimori Y, Baba H, Fujishiro M, Matsubara H, Numasaki H, Oyama T, Shinoda M, Takeuchi H, Teshima T, Udagawa H, Uno T, Barron JP. Comprehensive registry of esophageal cancer in Japan, 2004. Esophagus. 2012;9:75–98.CrossRef Ozawa S, Tachimori Y, Baba H, Fujishiro M, Matsubara H, Numasaki H, Oyama T, Shinoda M, Takeuchi H, Teshima T, Udagawa H, Uno T, Barron JP. Comprehensive registry of esophageal cancer in Japan, 2004. Esophagus. 2012;9:75–98.CrossRef
2.
go back to reference Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2014;34:280–300.PubMedCrossRef Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2014;34:280–300.PubMedCrossRef
3.
go back to reference Turner N, Grose R. Fibroblast growth factor signaling: from development to cancer. Nature Rev cancer. 2010;10:116–29.CrossRef Turner N, Grose R. Fibroblast growth factor signaling: from development to cancer. Nature Rev cancer. 2010;10:116–29.CrossRef
4.
5.
go back to reference Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010;2(62):62ra93. doi:10.1126/scitranslmed.3001451. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010;2(62):62ra93. doi:10.​1126/​scitranslmed.​3001451.
6.
go back to reference Kim HR, Kim DJ, Kang DR, Lee JG, Lim SM, Lee CY, Rha SY, Bae MK, Lee YJ, Kim SH, Ha SJ, Soo RA, Chung KY, Kim JH, Lee JH, Shim HS, Cho BC. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol. 2013;31:731–7.PubMedCrossRef Kim HR, Kim DJ, Kang DR, Lee JG, Lim SM, Lee CY, Rha SY, Bae MK, Lee YJ, Kim SH, Ha SJ, Soo RA, Chung KY, Kim JH, Lee JH, Shim HS, Cho BC. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol. 2013;31:731–7.PubMedCrossRef
7.
go back to reference Liao RG, Jung J, Tchaicha J, Wilkerson MD, Sivachenko A, Beauchamp EM, Liu Q, Pugh TJ, Pedamallu CS, Hayes DN, Gray NS, Getz G, Wong KK, Haddad RI, Meyerson M, Hammerman PS. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013;73:5195–205.PubMedPubMedCentralCrossRef Liao RG, Jung J, Tchaicha J, Wilkerson MD, Sivachenko A, Beauchamp EM, Liu Q, Pugh TJ, Pedamallu CS, Hayes DN, Gray NS, Getz G, Wong KK, Haddad RI, Meyerson M, Hammerman PS. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013;73:5195–205.PubMedPubMedCentralCrossRef
8.
go back to reference Fawdar S, Trotter EW, Li Y, Stephenson NL, Hanke F, Marusiak AA, Edwards ZC, Ientile S, Waszkowycz B, Miller CJ, Brognard J. Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer. Proc Natl Acad Sci USA. 2013;110:12426–31.PubMedPubMedCentralCrossRef Fawdar S, Trotter EW, Li Y, Stephenson NL, Hanke F, Marusiak AA, Edwards ZC, Ientile S, Waszkowycz B, Miller CJ, Brognard J. Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer. Proc Natl Acad Sci USA. 2013;110:12426–31.PubMedPubMedCentralCrossRef
9.
go back to reference Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y, Shimizu K, Tsujimoto G. MicroRNA-210 regulates cancer cell proliferation through Targeting Fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem. 2011;286:420–8.PubMedPubMedCentralCrossRef Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y, Shimizu K, Tsujimoto G. MicroRNA-210 regulates cancer cell proliferation through Targeting Fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem. 2011;286:420–8.PubMedPubMedCentralCrossRef
10.
go back to reference Shimada Y, Okumura T, Nagata T, Hashimoto I, Sawada S, Yoshida T, Fukuoka J, Shimizu K, Tsukada K. Expression analysis of fibroblast growth factor receptor-like 1 (FGFRL1) in esophageal squamous cell carcinoma. Esophagus. 2014;11:48–53.CrossRef Shimada Y, Okumura T, Nagata T, Hashimoto I, Sawada S, Yoshida T, Fukuoka J, Shimizu K, Tsukada K. Expression analysis of fibroblast growth factor receptor-like 1 (FGFRL1) in esophageal squamous cell carcinoma. Esophagus. 2014;11:48–53.CrossRef
11.
go back to reference Zhuang L, Falquet L, Trueb B. Genome-wide comparison of FGFRL1 with structurally related surface receptors. Exp Ther Med. 2010;1:161–8.PubMedPubMedCentral Zhuang L, Falquet L, Trueb B. Genome-wide comparison of FGFRL1 with structurally related surface receptors. Exp Ther Med. 2010;1:161–8.PubMedPubMedCentral
12.
go back to reference Shimada Y, Okumura T, Sekine S, Moriyama M, Sawada S, Matsui K, Yoshioka I, Hojo S, Yoshida T, Nagata T, Fukuoka J, Tsukada K. Expression analysis of ips cell—inductive genes in esophageal squamous cell carcinoma by tissue microarray. Anticancer Res. 2012;32:5507–14.PubMed Shimada Y, Okumura T, Sekine S, Moriyama M, Sawada S, Matsui K, Yoshioka I, Hojo S, Yoshida T, Nagata T, Fukuoka J, Tsukada K. Expression analysis of ips cell—inductive genes in esophageal squamous cell carcinoma by tissue microarray. Anticancer Res. 2012;32:5507–14.PubMed
13.
go back to reference Sobin LH, Wittekind Ch, editors. TNM Classification of Malignant Tumors. 6th ed. New York: Wiley-Liss; 2002. p. 60–4. Sobin LH, Wittekind Ch, editors. TNM Classification of Malignant Tumors. 6th ed. New York: Wiley-Liss; 2002. p. 60–4.
14.
go back to reference Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T. Characterization of 21 newly established esophageal cancer cell lines. Cancer. 1992;69:277–84.PubMedCrossRef Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T. Characterization of 21 newly established esophageal cancer cell lines. Cancer. 1992;69:277–84.PubMedCrossRef
15.
go back to reference Sugiura K, Ozawa S, Kitagawa Y, Ueda M, Kitajima M. Co-expression of aFGF and FGFR-1 is predictive of a poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep. 2007;17:557–64.PubMed Sugiura K, Ozawa S, Kitagawa Y, Ueda M, Kitajima M. Co-expression of aFGF and FGFR-1 is predictive of a poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep. 2007;17:557–64.PubMed
16.
go back to reference Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet. 2014;46:467–73.PubMedPubMedCentralCrossRef Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet. 2014;46:467–73.PubMedPubMedCentralCrossRef
17.
go back to reference Song Y, Li L, Ou Y, Gao Z, Li E, Li X, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509:91–5.PubMedCrossRef Song Y, Li L, Ou Y, Gao Z, Li E, Li X, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509:91–5.PubMedCrossRef
18.
go back to reference Zhang C, Fu L, Fu J, Hu L, Yang H, Rong TH, Li Y, Liu H, Fu SB, Zeng YX, Guan XY. Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clin Cancer Res. 2009;15:4017–27.PubMedCrossRef Zhang C, Fu L, Fu J, Hu L, Yang H, Rong TH, Li Y, Liu H, Fu SB, Zeng YX, Guan XY. Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clin Cancer Res. 2009;15:4017–27.PubMedCrossRef
19.
go back to reference Kato H, Arao T, Matsumoto K, Fujita Y, Kimura H, Hayashi H, Nishiki K, Iwama M, Shiraishi O, Yasuda A, Shinkai M, Imano M, Imamoto H, Yasuda T, Okuno K, Shiozaki H, Nishio K. Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol. 2013;42:1151–8.PubMedPubMedCentral Kato H, Arao T, Matsumoto K, Fujita Y, Kimura H, Hayashi H, Nishiki K, Iwama M, Shiraishi O, Yasuda A, Shinkai M, Imano M, Imamoto H, Yasuda T, Okuno K, Shiozaki H, Nishio K. Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol. 2013;42:1151–8.PubMedPubMedCentral
20.
go back to reference Kim Y, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol. 2014;32:121–8.PubMedPubMedCentralCrossRef Kim Y, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol. 2014;32:121–8.PubMedPubMedCentralCrossRef
21.
go back to reference Zhang Y, Hiraishi Y, Wang H, Sumi KS, Hayashido Y, Toratani S, Kan M, Sato JD, Okamoto T. Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. Int J Cancer. 2005;117:166–8.PubMedCrossRef Zhang Y, Hiraishi Y, Wang H, Sumi KS, Hayashido Y, Toratani S, Kan M, Sato JD, Okamoto T. Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. Int J Cancer. 2005;117:166–8.PubMedCrossRef
22.
go back to reference Nemoto T, Ohashi K, Akashi T, Johnson JD, Hirokawa K. Overexpression of protein tyrosin kinases in human esophageal cancer. Pathobiology. 1997;65:195–203.PubMedCrossRef Nemoto T, Ohashi K, Akashi T, Johnson JD, Hirokawa K. Overexpression of protein tyrosin kinases in human esophageal cancer. Pathobiology. 1997;65:195–203.PubMedCrossRef
23.
go back to reference Chong IY, Cunningham D, Barber LJ, Campbell J, Chen L, Kozarewa I, et al. The genomic landscape of oesophagogastric junctional adenocarcinoma. J Pathol. 2013;231:301–10.PubMedCrossRef Chong IY, Cunningham D, Barber LJ, Campbell J, Chen L, Kozarewa I, et al. The genomic landscape of oesophagogastric junctional adenocarcinoma. J Pathol. 2013;231:301–10.PubMedCrossRef
24.
go back to reference Söderberg O, Gullberg M, Jarvius M, Ridderstråle K, Leuchowius KJ, Jarvius J, Wester K, Hydbring P, Bahram F, Larsson LG, Landegren U. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006;3:995–1000.PubMedCrossRef Söderberg O, Gullberg M, Jarvius M, Ridderstråle K, Leuchowius KJ, Jarvius J, Wester K, Hydbring P, Bahram F, Larsson LG, Landegren U. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006;3:995–1000.PubMedCrossRef
25.
go back to reference Weibrecht I, Leuchowius KJ, Clausson CM, Conze T, Jarvius M, Howell WM, Kamali-Moghaddam M, Söderberg O. Proximity ligation assays: a recent addition to the proteomics toolbox. Expert Rev Proteomics. 2010;7:401–9.PubMedCrossRef Weibrecht I, Leuchowius KJ, Clausson CM, Conze T, Jarvius M, Howell WM, Kamali-Moghaddam M, Söderberg O. Proximity ligation assays: a recent addition to the proteomics toolbox. Expert Rev Proteomics. 2010;7:401–9.PubMedCrossRef
26.
go back to reference Sleeman M, Fraser J, McDonald M, Yuan S, White D, Grandison P, Kumble K, Watson JD, Murison JG. Identification of a new fibroblast growth factor receptor, FGFR5. Gene. 2001;271:171–82.PubMedCrossRef Sleeman M, Fraser J, McDonald M, Yuan S, White D, Grandison P, Kumble K, Watson JD, Murison JG. Identification of a new fibroblast growth factor receptor, FGFR5. Gene. 2001;271:171–82.PubMedCrossRef
27.
go back to reference Trueb B, Zhuang L, Taeschler S, Wiedemann M. Characterization of FGFRL1, a novel fibroblast growth factor (FGF) receptor preferentially expressed in skeletal tissues. J Biol Chem. 2003;278:33857–65.PubMedCrossRef Trueb B, Zhuang L, Taeschler S, Wiedemann M. Characterization of FGFRL1, a novel fibroblast growth factor (FGF) receptor preferentially expressed in skeletal tissues. J Biol Chem. 2003;278:33857–65.PubMedCrossRef
28.
go back to reference Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M. Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996;271:15292–7.PubMedCrossRef Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M. Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996;271:15292–7.PubMedCrossRef
Metadata
Title
Role of fibroblast growth factor receptors in esophageal squamous cell carcinoma
Authors
Yutaka Shimada
Tomoyuki Okumura
Yoshinori Takei
Kazuaki Watanabe
Takuya Nagata
Takashi Hori
Soken Tsuchiya
Kazuhiro Tsukada
Kazuharu Shimizu
Publication date
01-01-2016
Publisher
Springer Japan
Published in
Esophagus / Issue 1/2016
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-015-0486-4

Other articles of this Issue 1/2016

Esophagus 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.